Everolimus (40-O-(2-hydroxyethyl)-rapamycin, RAD001/Afinitor®) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) which is currently approved for the treatment of advanced renal cell carcinoma and progressive neuroendocrine tumors of pancreatic origin (PNET) [7], [8]. This evidence concerns the gene MTOR and primitive neuroectodermal tumor.